黄斑浮腫治療薬市場:パイプラインレビュー(2019年下半期)

◆英語タイトル:Macular Edema - Pipeline Review, H2 2019
◆商品コード:GDATA20MY0583
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2019年12月27日
◆ページ数:87
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Macular Edema – Pipeline Review, H2 2019
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Macular Edema – Pipeline Review, H2 2019, provides an overview of the Macular Edema (Ophthalmology) pipeline landscape.

Macular edema is swelling or fluid retention in a specialized part of the retina called the macula. Symptoms of macular edema include blurred or wavy central vision and/or colors appear changed. There are many causes of macular edema. It is frequently associated with diabetes, where damaged blood vessels in the retina begin to leak fluids, including small amounts of blood, into the retina. Other causes include retinal vein occlusion, side effects of certain medications and certain genetic disorders, such as retinoschisis or retinitis pigmentosa.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Macular Edema – Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Macular Edema (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Macular Edema (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 1, 1, 2, 12, 1 and 1 respectively.

Macular Edema (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Macular Edema (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Macular Edema (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Macular Edema (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Macular Edema (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Macular Edema (Ophthalmology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Macular Edema (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Macular Edema (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Macular Edema – Overview
Macular Edema – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Macular Edema – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Macular Edema – Companies Involved in Therapeutics Development
Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Profarma
Promedior Inc
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB
Macular Edema – Drug Profiles
Macular Edema – Dormant Projects
Macular Edema – Discontinued Products
Macular Edema – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Macular Edema, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Macular Edema - Pipeline by Anew Oncology Inc, H2 2019
Macular Edema - Pipeline by AsclepiX Therapeutics Inc, H2 2019
Macular Edema - Pipeline by Celon Pharma SA, H2 2019
Macular Edema - Pipeline by Clearside BioMedical Inc, H2 2019
Macular Edema - Pipeline by Coherus BioSciences Inc, H2 2019
Macular Edema - Pipeline by Formycon AG, H2 2019
Macular Edema - Pipeline by Lupin Ltd, H2 2019
Macular Edema - Pipeline by Luye Pharma Group Ltd, H2 2019
Macular Edema - Pipeline by Mabion SA, H2 2019
Macular Edema - Pipeline by OMEICOS Therapeutics GmbH, H2 2019
Macular Edema - Pipeline by PharmAbcine Inc, H2 2019
Macular Edema - Pipeline by Profarma, H2 2019
Macular Edema - Pipeline by Promedior Inc, H2 2019
Macular Edema - Pipeline by Sustained Nano Systems LLC, H2 2019
Macular Edema - Pipeline by Taiwan Liposome Co Ltd, H2 2019
Macular Edema - Pipeline by Targeted Therapy Technologies LLC, H2 2019
Macular Edema - Pipeline by Tarsius Pharma Ltd, H2 2019
Macular Edema - Pipeline by Xbrane Biopharma AB, H2 2019
Macular Edema - Dormant Projects, H2 2019
Macular Edema - Discontinued Products, H2 2019

【掲載企業】

Anew Oncology Inc
AsclepiX Therapeutics Inc
Celon Pharma SA
Clearside BioMedical Inc
Coherus BioSciences Inc
Formycon AG
Lupin Ltd
Luye Pharma Group Ltd
Mabion SA
OMEICOS Therapeutics GmbH
PharmAbcine Inc
Profarma
Promedior Inc
Sustained Nano Systems LLC
Taiwan Liposome Co Ltd
Targeted Therapy Technologies LLC
Tarsius Pharma Ltd
Xbrane Biopharma AB

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[黄斑浮腫治療薬市場:パイプラインレビュー(2019年下半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆